Medical Marijuana for Multiple Sclerosis in New Jersey
Multiple sclerosis is a direct qualifying condition for the NJ Medicinal Cannabis Program, and it is one of the conditions with the most rigorous pharmaceutical-grade evidence supporting cannabis's efficacy. Nabiximols (Sativex) — a 1:1 THC:CBD oromucosal spray — has demonstrated in multiple Phase III randomized controlled trials that cannabis reduces MS spasticity in patients who have not adequately responded to standard anti-spasticity medications. While Sativex is not FDA-approved for sale in the US, it is approved in more than 30 countries, and NJ medical cannabis patients access the same active compounds through the state program.
Does Multiple Sclerosis Qualify for the NJ Medicinal Cannabis Program?
Yes. Multiple sclerosis is a direct qualifying condition. A diagnosis from any licensed provider — a neurologist, an MS specialist, or a primary care physician who has documented your MS diagnosis — is accepted. You do not need to be under active neurological care to qualify; historical records confirming the diagnosis are sufficient.
For MS patients, the most commonly addressed symptoms at PremierMD are spasticity, pain, sleep disruption, and bladder dysfunction. Cannabis certification at PremierMD covers the full symptom picture — not just the qualifying diagnosis.
How Medical Cannabis Helps Multiple Sclerosis
Spasticity
MS spasticity — the involuntary muscle stiffness, spasms, and cramping that affects an estimated 80% of MS patients over the course of the disease — is the symptom with the strongest evidence base for cannabis treatment.
The mechanism: CB1 receptors are highly expressed in the motor cortex and spinal cord, the primary sites of MS-related demyelination and inflammation that produce spasticity. THC and CBD, acting on these receptors, reduce the abnormal excitatory signaling that produces spastic muscle activity. This is not a systemic muscle relaxant effect — it is site-specific modulation at the neural circuits driving the spasticity.
Nabiximols (Sativex), the pharmaceutical 1:1 THC:CBD spray, has undergone multiple Phase III RCTs specifically in MS spasticity patients who failed standard oral anti-spasticity medications (baclofen, tizanidine). In the pivotal SAVANT trial and multiple prior studies, nabiximols significantly reduced spasticity scores and patient-reported spasm frequency and severity compared to placebo. This evidence base is what supported regulatory approval in 30+ countries.
Oral baclofen and tizanidine — the standard pharmacological treatments for spasticity — have significant cognitive side effects and variable efficacy. Cannabis's spasticity-specific mechanism makes it a valuable alternative or add-on, particularly for patients whose spasticity control is inadequate with standard agents.
Pain
MS pain is complex: it includes neuropathic pain (from demyelination and nerve damage), musculoskeletal pain from spasticity and abnormal gait, and headache. The NASEM 2017 report found "substantial evidence" for cannabis in treating chronic pain; neuropathic pain — the most difficult pain type for standard analgesics — is particularly well-represented in the MS literature.
Sleep
MS disrupts sleep through multiple mechanisms: pain, spasticity at night, bladder dysfunction requiring night waking, and temperature dysregulation. Cannabis's analgesic, antispasmodic, and sleep-promoting effects address the most common sleep-disrupting symptoms simultaneously.
Bladder Dysfunction
Urinary urgency and incontinence are among the most common and functionally disabling MS symptoms. Nabiximols trials have included bladder dysfunction as a secondary endpoint, with some studies finding reductions in urinary urgency episodes. CB1 receptors are present in the bladder and spinal pathways controlling bladder function.
What the Research Shows
- Nabiximols (Sativex) and spasticity: Multiple Phase III RCTs across several thousand MS patients demonstrate significant spasticity reduction; regulatory approval in >30 countries. This is the most rigorous cannabis evidence in any condition short of the Epidiolex epilepsy trials.
- CAMS study (UK, 2003): One of the earliest large RCTs, testing oral THC:CBD extract in 611 MS patients. Found significant patient-reported spasm reduction and quality of life improvement.
- Neuropathic pain: Multiple RCTs of smoked cannabis and oral extracts in neuropathic pain (not MS-specific) show significant benefit; MS neuropathic pain trials show similar patterns.
- CUPID trial: A long-term RCT of THC in MS patients found no disease-modifying effect — confirming cannabis does not slow MS progression. It is a symptom management tool.
What to Bring to Your PremierMD Evaluation for MS
Bring:
- MS diagnosis records — neurologist records, MRI reports, or primary care chart notes documenting MS diagnosis. The type of MS (relapsing-remitting RRMS, secondary progressive SPMS, primary progressive PPMS) does not affect qualifying eligibility.
- Your current MS treatment list — disease-modifying therapies (DMTs: interferons, glatiramer acetate, natalizumab, ocrelizumab, siponimod, etc.) and symptom medications (baclofen, tizanidine, amantadine for fatigue, oxybutynin for bladder). Cannabis interactions with some of these require assessment.
- A description of which symptoms are most burdensome: spasticity, pain, sleep, fatigue, bladder, or mood. This guides product selection.
Insurance Coverage for MS Patients
The physician evaluation at PremierMD is billed to Medicare, Medicaid, or your commercial plan as a standard outpatient visit. MS patients are often on Medicare (via disability) or commercial insurance. For dual-eligible patients, $0 with PremierMD designated as Medicaid PCP.
See: Does Insurance Cover a Medical Marijuana Evaluation in NJ?
Frequently Asked Questions: Cannabis and MS in NJ
Does cannabis slow MS disease progression?
No. The CUPID trial and other long-term data have found no evidence that cannabis modifies the underlying disease course. Cannabis manages symptoms; disease modification requires your neurologist's DMT regimen.
I am already on baclofen — can I still use cannabis?
Yes, and cannabis is often used alongside baclofen and tizanidine for patients with inadequate spasticity control. Your provider will assess your current anti-spasticity regimen and whether cannabis is appropriate as an add-on. Some patients are able to reduce baclofen over time, but this should happen under your neurologist's guidance.
Can MS patients use any delivery method?
Smoking and vaping are options some MS patients find effective for rapid spasm relief. Oral products (capsules, tinctures, edibles) provide longer-duration effects relevant for overnight symptom management. For MS bladder dysfunction, suppository products may be relevant. Your provider will discuss the full delivery option landscape.
Does cannabis help MS fatigue?
Fatigue is one of the most common and disabling MS symptoms, but evidence for cannabis in MS fatigue specifically is mixed. THC can both reduce fatigue (by improving sleep) and contribute to fatigue (at sedating doses). Product selection timing matters; your provider will guide this.
Will cannabis interact with my MS disease-modifying therapy?
Most DMTs are biologics or large-molecule immunomodulators with minimal interaction with cannabis through standard hepatic enzyme pathways. Some oral DMTs (fingolimod, siponimod, teriflunomide) metabolized by CYP enzymes have theoretical interaction risk. Your PremierMD provider will review your DMT for interaction risks.
Get Evaluated at PremierMD
Check your eligibility or register as a patient to schedule your evaluation.
